Biotech Values

[biocqr]

MRTX> only 31K shares traded so far on this news...

Orphan Drug status for mocetinostat

The FDA designates Mirati Therapeutics' (MRTX +0.1%) spectrum selective HDAC inhibitor mocetinostat an Orphan Drug for the treatment of myelodysplastic syndrome (MDS). Mirati is developing the product in combination with Vidaza as a treatment for intermediate and high-risk MDS and as a single agent treatment for diffuse large B-cell lymphoma and bladder cancer.

The very low trading volume makes it an unsuitable name for me to pursue.